Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 15

Results For "RSE"

2070 News Found

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036
Healthcare | June 01, 2026

Europe Treponema pallidum tests market to grow at 3% CAGR through 2036

Increasing syphilis cases, stronger STI surveillance initiatives, and growing emphasis on early diagnosis are expected to support sustained demand


Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections
Drug Approval | June 01, 2026

Wockhardt wins FDA nod for new antibiotic ZAYNICH against drug-resistant infections

The approval marks a major milestone in the global fight against antimicrobial resistance


Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial
Clinical Trials | June 01, 2026

Pfizer’s BRAFTOVI combo doubles progression-free survival in aggressive colorectal cancer trial

The results confirm the study’s primary endpoint of objective response rate and now deliver a striking signal in progression-free survival


Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial
Clinical Trials | June 01, 2026

Pfizer’s drug combo shows strong survival results in aggressive prostate cancer trial

This marks one of the most closely watched oncology readouts at this year’s medical congress


Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India
Healthcare | June 01, 2026

Oval Fertility launches in Hyderabad, introduces Astec Chronos AI-powered IVF tech to India

Aims to bridge transparency gaps in fertility care, with focus on successful patient outcomes, placing healthy live birth outcomes at the centre of treatment journeys


Ardena appoints Ariane de Ganck as Chief Scientific Officer
People | June 01, 2026

Ardena appoints Ariane de Ganck as Chief Scientific Officer

Ariane brings a strong track record within Ardena, including her leadership of the company’s drug product division since 2022


Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%
R&D | May 31, 2026

Bristol Myers Squibb’s mezigdomide cuts myeloma progression risk by 52%

MeziKd delivered stronger response rates across multiple patient groups, including those receiving second- and third-line treatment and patients with higher-risk disease


AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia
Clinical Trials | May 31, 2026

AbbVie bags major European label expansion for VENCLYXTO in chronic lymphocytic leukemia

The expanded indication is backed by data from the Phase 3 AMPLIFY and GLOW trials and the Phase 2 CAPTIVATE study,


Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial
Clinical Trials | May 30, 2026

Pfizer's LORBRENA delivers landmark seven-year survival results in advanced lung cancer trial

The findings mark one of the longest progression-free survival outcomes ever reported in advanced lung cancer